England, James T. http://orcid.org/0000-0002-9692-1634
McNamara, Caroline J.
Kennedy, James A.
Capo-Chichi, Jose-Mario
Huang, Jingyue http://orcid.org/0000-0002-8640-9119
Arruda, Andrea
Nye, Taylor
Cheung, Verna
Claudio, Jaime O.
Maze, Dawn http://orcid.org/0000-0002-4598-9380
Sibai, Hassan
Tierens, Anne http://orcid.org/0000-0002-5350-8313
Tsui, Hubert
Bankar, Aniket
Xu, Wei
Stockley, Tracy http://orcid.org/0000-0002-4476-9722
Gupta, Vikas http://orcid.org/0000-0002-1419-8607
Funding for this research was provided by:
Princess Margaret Cancer Foundation
Elizabeth and Tony Comper MPN Foundation
Article History
Received: 18 December 2021
Revised: 1 March 2022
Accepted: 9 March 2022
First Online: 26 March 2022
Competing interests
: CM has received honoraria from Novartis. DM has received research support from Novartis, Celgene/Bristol-Myers Squibb, PharmaEssentia, Takeda; honoraria from Novartis, Celgene/Bristol-Myers Squibb; served on the advisory board of Novartis, and provided consultancy for Pfizer. VG received research funding through his institution and honoraria from Novartis and Incyte and has served on the advisory board of Novartis, Incyte, BMS-Celgene, Abb Vie, Sierra Oncology, Pfizer, Takeda, and Constellation Biopharma; The remaining authors stated that they have no conflicts of interest.